Skip to main content

Table 2 Impact of mpMRI tumor staging on RT treatment prescription (target volume, doses and hormonal therapy)

From: Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy

Characteristics

DRE/TRUS n (%)

mpMRI n (%)

p value

T-category

T1–T2a

239 (87.2)

67 (24.5)

<0.001

T2b–T2c

30 (11.0)

157 (57.3)

T3–T4

5 (1.8)

50 (18.2)

Risk group

Low-risk (LR)

95 (34.7)

32 (11.7)

<0.001

Intermediate-risk (IR)

127 (46.4)

163 (59.5)

High-risk (HR)

52 (19.0)

79 (28.8)

Target volume

VVSS prophylactic

174 (63.5)

192 (70.1)

<0.001

T3a + T3b + T4

5 (1.8)

50 (18.2)

Doses

Low

95 (34.7)

32 (11.7)

<0.001

High

179 (65.3)

242 (88.3)

Hormonal therapy

HR and IR (Initial criteria)a

 No

182 (66.4)

158 (57.7)

0.035

 Yes

92 (33.6)

116 (42.3)

HR and IR (MSKCC criteria)b

 No

149 (54.4)

103 (37.6)

<0.001

 Yes

125 (45.6)

171 (62.4)

Hormonal therapy in IR patients

Initial criteria

 No

220 (80.3)

221 (80.7)

0.914

 Yes

54 (19.7)

53 (19.3)

MSKCC criteria

  

0.002

 No

180 (65.7)

144 (52.6)

 Yes

94 (34.3)

130 (47.4)

 

Hormonal therapy in HR patients

No

222 (81.0)

195 (71.2)

0.007

Yes

52 (19.0)

79 (28.8)

  1. VVSS seminal vesicles, DRE/TRUS digital rectal exam/transrectal ultrasound
  2. a Initial criteria: GS of 7 (4 + 3), or three unfavourable IR factors (T2b + PSA 10-20 ng/mL + GS 3 + 4), or T2c by DRE/TRUS
  3. b MSKCC criteria: GS 4 + 3, or at least two IR factors, or at least one IR factor and a positive prostate biopsy (ppb) percentage greater than 50 %